Efficacy of multiple anticancer therapies may depend on host immune response

Kritika Karri, Dhundy R. Bastola

Research output: Contribution to journalArticlepeer-review


The host immune system is a key player in anticancer therapy response and resistance. Although the impact of host immune response in the 'war against cancer' has been studied and it has been the basis for immunotherapy, understanding of its role in attenuating the action of conventional anticancer therapies is an area that has not been fully explored. In spite of advances in systemic therapy, the 5-year survival rate for adenocarcinoma is still a mere 13% and the primary reason for treatment failure is believed to be due to acquired resistance to therapy. Hence, there is a need for identifying reliable biomarkers for guided treatment of lung and colon adenocarcinoma and to better predict the outcomes of specific anticancer therapies. In this work, gene expression data were analyzed using public resources and this study shows how host immune competence underscores the efficacy of various anticancer therapies. Additionally, the result provides insight on the regulation of certain biochemical pathways relating to the immune system, and suggests that smart chemotherapeutic intervention strategies could be based on a patient's immune profile.

Original languageEnglish (US)
Pages (from-to)773-787
Number of pages15
JournalAdvances in Science, Technology and Engineering Systems
Issue number3
StatePublished - Jan 1 2017


  • Alkylating agents
  • Anti-angiogenesis
  • Antimetabolite
  • Biomarker
  • Colon adenocarcinoma
  • Complete Remission
  • GSEA
  • Immune response
  • Lung adenocarcinoma
  • Mitotic inhibitors
  • Progressive Disease

ASJC Scopus subject areas

  • Engineering (miscellaneous)
  • Physics and Astronomy (miscellaneous)
  • Management of Technology and Innovation


Dive into the research topics of 'Efficacy of multiple anticancer therapies may depend on host immune response'. Together they form a unique fingerprint.

Cite this